Donor-derived Mesenchymal Stromal Cells, Alemtuzumab, Co-stimulation Blockade and Sirolimus for Tolerance Induction in Adult Kidney Allograft Recipients (ITN062ST)
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2018
At a glance
- Drugs Alemtuzumab (Primary) ; Belatacept (Primary) ; Sirolimus (Primary) ; Mesenchymal stem cell therapy; Mycophenolate; Mycophenolate mofetil; Prednisone
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms TEACH
- 30 Jul 2018 Status changed from not yet recruiting to recruiting.
- 07 Jun 2018 Planned End Date changed from 1 Sep 2024 to 1 Aug 2025.
- 07 Jun 2018 Planned primary completion date changed from 1 Sep 2024 to 1 Aug 2025.